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Background: There is no consensus regarding the secondary cytoreduction surgery (CRS) in recurrent ovarian cancer
patients. The present study aims to determine the value of secondary CRS and the eligible subgroup for this procedure.
Methods: 96 platinum-sensitive recurrent ovarian cancer patients were recruited from Jiangsu Institute of Cancer
Research between 1992 and 2011. Follow-up was conducted based on the surveillance protocol of MD Anderson
Cancer Center. Cox proportional hazards model and log-rank test were used to assess the associations between the
survival durations and covariates. Logistic regression analysis was used to explore optimal secondary CRS related factors.
Results: Optimal secondary CRS was associated with time to progression (TTP) and overall survival (OS) in patients
(p < 0.01 both). Optimal secondary CRS and asymptomatic recurrent were similarly associated with longer OS
(median: 79.2 vs. 53.9 and 76.1 vs. 56.0 months with p = 0.02 and p = 0.04, respectively) and TTP (median: 13.9 vs. 10.5
and 19.3 vs. 9.0 months with p = 0.02 and p = 0.03, respectively) than counterparts. Optimal initial CRS (p = 0.01),
asymptomatic recurrent (p = 0.02) and longer progression-free survival duration (p = 0.02) were the independent
indicators of optimal secondary CRS.
Conclusions: Optimal secondary CRS had survival benefit for platinum-sensitive epithelial ovarian cancer.
Asymptomatic recurrent was one of the recruited factors for this procedure.
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Epithelial ovarian cancer (EOC) is the fifth most com-
mon cause of cancer mortality in United States and
Chinese women [1,2]. The standard primary treatment
paradigm of EOC includes optimal primary cyto-
reductive surgery (CRS) followed by platinum/paclitaxel
based chemotherapy. Although more than half of EOC
patients results in a complete clinical response (CCR)
through initial therapy, achieving complete cure is infre-
quent. In fact, about 75% EOC patients develop recurrent
disease within 2 years and the mean 5-year survival rate
following the radiological defined recurrence is less than
10% [3]. The management of recurrent diseases is one of* Correspondence: cxxxxcyd@gmail.com
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reproduction in any medium, provided the orthe key topics and is less clear than that of primary EOC.
Salvage chemotherapy and secondary CRS were the two
major therapeutic choices for the recurrent ovarian cancer.
Despite the significant progress in chemotherapy and bio-
logical agents, surgery is still the cornerstone of recurrent
patients’ management. Secondary CRS may be possible to
improve the chance of objective response and/or a longer
interval of second remission. Exploring the potential bene-
ficial subpopulation and selection criteria of these two
treatments is indispensable.
Observational studies have explored that secondary
CRS may improve the survival duration of recurrent
EOC patients. At least in platinum-sensitive recurrent
EOC, the optimal secondary CRS shows a certain positive
significance [4-9]. In addition to the potential benefit of
secondary CRS, defining the specific population that might
best benefit from this surgery is equaled important. Se-
condary CRS should be benefit to carefully selected patientsThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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resection was general accepted. Presently, identifying the
eligible subgroup for the potentially morbidity-inducing
procedure remains a clinical challenge and in practice,
gynecologic oncologists use their own qualifying cri-
teria will vary from one to others. The series trials of
DESKTOP identified an independently predictive score
for complete resection comprehensive of good perfor-
mance status, complete resection at primary surgery, and
the absence of ascites [10,11]. Zang et, al. found a pa-
tients’ selected model for optimal secondary CRS in re-
current ovarian cancer includes FIGO stage, residual
disease after primary surgery, progression-free interval,
ECOG performance status, CA125 at recurrence, ascites
at recurrence. Our previous study revealed that rising
CA-125 levels optimized the secondary CRS in asymp-
tomatic recurrent EOC [12]. Other factors predict surgery
outcome of secondary CRS includes progression-freeTable 1 Patient characteristics of the study population
Characteristic Percentage (%)/Median (range)
Age (years) 61.6 (26–82)
Baseline CA-125 level (U/mL) 582 (5–24260)













<1 cm 62 (64.6)
1–2 cm 3 (3.1)








Neo-adjuvant chemotherapy 68 (70.6)
Paclitaxel-based 82 (85.4)
FIGO the International Federation of Gynecology and Obstetrics.survival (PFS) from primary treatment to recurrence,
and number of recurrent tumors [13].
In the present study, we retrospectively evaluated
platinum-sensitive recurrent ovarian cancer patients who
underwent secondary CRS. Factors affecting the outcome
of secondary CRS were analyzed to reveal those who po-
tential benefit with the opportunity for this procedure.
Methods
Study population
Present research was approved by Jiangsu Institute of
Cancer Research (JICR). We identified 96 platinum-
sensitive recurrent EOC patients at JICR from clinical
stations between January 1, 1992 and January 1, 2011.
Among them, 43 cases underwent secondary CRS. Those
who did not undergo the standard first line treatment
and achieved CCR or platinum resistance recurrent were
excluded. Secondary CRS as a selective procedure wasTable 2 Univariate analysis of survival-related
characteristics in platinum-sensitive recurrent
ovarian cancer

























Nadir CA-125 1.02(1.00–1.03) 1.03(1.00–1.06)
CRS cytoreduction surgery; OS overall survival; TTP time to progression;
PFS progression-free survival.
Table 3 Multivariate analysis of survival-related
characteristics in platinum-sensitive recurrent
ovarian cancer











Nadir CA-125 1.02(1.00–1.02) 1.03(1.00–1.04)
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intended purpose of tumor reduction. After primary ther-
apy, the routine follow-up protocol was conducted as de-
scribed previously. The Response Evaluation Criteria in
Solid Tumors (RECIST) criterion was used to assess treat-
ment response and tumor progression [14-16]. The clinico-
pathological data including the histological type and grade
of the tumor [17,18], stage of the disease [19], volume of
ascites, time to progression, management of primary and
recurrent disease, and time of death or last follow-up.
Pathological diagnoses of recruited cases were reviewed by
two JICR pathologists, namely, X. Xu and L. Hou.
Definition of clinical response and surveillance
The definition of CCR includes the absence of tumor-
associated clinical symptoms and residual tumor on the
physical examination, EOC-negative imaging study re-
sults and a serum CA-125 concentration below the upper
limit of the normal range (ULN = 35U/mL) in the current
study. Clinical recurrent was identified as the occurrenceFigure 1 Patients who underwent optimal secondary CRS had longerof any new measurable lesion through imaging stud-
ies or clinical examination [15]. Patients underwent
neoadjuvant chemotherapy followed by interval CRS.
Platinum-sensitive recurrent was generally referring to
the progression of the free interval at least 6 months
from the completion of primary therapy. According to
most of the gynecologists, secondary CRS is defined as
an debulking procedure performed at some time remote
(generally disease free interval of more than 6 months)
from the completion of primary treatment with the
intended purpose of tumor reduction. The criterion of
optimal CRS was the threshold of residual tumor ≤ 1 cm
or macroscopic free and suboptimal debulking was de-
fined as more than 1 cm of nodules left. The overall sur-
vival (OS) duration was defined as the time from the
disease diagnosis to death or last follow-up. PFS was the
length of time during and after initial therapy wherein
the patient’s condition does not worsen. Time to pro-
gression (TTP) was a measure of time from radiological
defined relapse to the disease starts to get worse in
present study.
Statistical analysis
Cox proportional hazards model was used to assess the
relationship between the clinical characteristics and the
OS and TTP. Step-wise regression was conducted to
build the multivariate models. The log-rank test was
used to assess this relationship. Logistic regression ana-
lysis was used to explore optimal secondary CRS related
factors. The p values < 0.05 was considered statistically
significant. All analyses were conducted using the SPSS




The clinicopathological characteristics of all patients in-
cluded in the present study were given in Table 1. High-OS and TTP durations than those who did not undergo (1A, 1B).
Figure 2 Symptomatic recurrent patients who underwent secondary CRS had shorter OS (A) and TTP (B) durations than asymptomatic ones
(2A, 2B).
Table 4 Logistic regression of optimal secondary
CRS-associated factors in platinum-sensitive recurrent
ovarian cancer
Variable Univariate Multivariate
Exp(B) Sig Exp(B) Sig
Age 1.01 0.12 1.00 0.43
Ascites 1.40 0.02 1.33 0.15
Initial CRS 2.63 0.00 2.29 0.01
PFS 2.02 0.01 1.85 0.02
Recurrent status 1.96 0.00 1.52 0.02
Stage 1.25 0.00 1.20 0.19
CA-125 at recurrent 1.05 0.15 1.02 0.36
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13 (13.5%), respectively, and serous carcinoma cases was
67 (69.8%). Median follow-up time was 37.6 months
(interquartile range, 20.2 months to 69.0 months) in the
living patients at the beginning of our analysis. The recur-
rent patients underwent secondary CRS were reported ex-
periencing pain (2 patients), gastrointestinal dysfunction
(8 cases), and/or mass effect (7 cases) and others (7 cases).
Nineteen cases were asymptomatic biochemistry recur-
rence. In all 96 patients who underwent platinum-sensitive
clinical recurrent, 48 (50.0%) patients were CA-125 indi-
cated asymptomatic relapse.
Survive related factors in platinum-sensitive recurrent
ovarian cancer
Univariate Cox proportional hazards model revealed that
FIGO stage, pathological grade, outcome of CRS, nadir
CA-125 level, ascities and PFS were associate with OS and
TTP in all patients (Table 2). Multivariate analysis revealed
that grade, nadir CA-125 level, optimal secondary CRS,
ascities and PFS were independent OS and TTP predictors
in platinum-sensitive recurrent EOC (Table 3).
The OS and TTP durations of ovarian cancer patients
who underwent optimal secondary were longer than those
who did not undergo (p = 0.02 and p = 0.02 respectively;
Figure 1A and B). In patients underwent secondary CRS,
the OS and TTP durations of asymptomatic cases were
longer than those of symptomatic ones (p = 0.04 and p =
0.03 respectively; Figure 2A and B).
Optimal secondary CRS associated factors
To explore the potential factors related to optimal sec-
ondary CRS, we performed logistic regression analysis in
platinum-sensitive recurrent ovarian cancer patients, we
found that optimal initial CRS (p = 0.01), asymptomatic
recurrent status (p = 0.02) and longer progression-free
survival duration (p = 0.02) were the independent indica-
tors for OS and TTP (as seen in Table 4).Discussion
The high recurrence rate and the lack of effective treat-
ments incurs therapeutic dilemma in the management of
EOC. Presently, the standard care of recurrent EOC is sal-
vage chemotherapy but not SCR for recurrence is consi-
dered to be incurable. The Secondary CRS is a treatment
option for selected patients with recurrent EOC. Though
being examined by several retrospective or nonrandomized
prospective studies, the prognostic role and the uti-
lity criterion of secondary CRS still remain controversial
[8,20-26]. One prospective study suggested that optimal
secondary CRS was feasible for the most of patients with
recurrent EOC and confers survival benefit while com-
bined with salvage chemotherapy [26]. On the contrary,
another study stated that secondary CRS does not im-
prove PFS or OS in patients underwent initial optimal
surgery [27]. Ongoing prospective multi-centers trials
(DESKTOP III and Gynecologic Oncology Group Proto-
col 213) to probe the survival benefit of secondary CRS
and second line chemotherapy in patients with recurrent
EOC may help to settle disputes partly [28]. Other factors
including performance status, preoperative and post-
operative chemotherapy, histologic type, ascites, elevated
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rence were reported to be prognostic factors [4,20,26,29].
In our series, tumor grade, ascites, nadir serum CA 125
level, optimal secondary CRS and progression-free interval
were independent prognostic factors for TTP and OS.
It is generally believed that secondary CRS has a sur-
vival benefit in select platinum-sensitive patients with re-
current ovarian cancer. Who will benefit from or say
will appropriate for secondary CRS is another important
concern on this topic. Minimal residual tumor and lon-
ger progression-free interval were reported to indicate
improving survival outcomes in most studies [5,8,30,31].
On the other hand, some studies found residual tumor and
progression-free interval had no impact of on prognosis in
recurrent EOC underwent secondary CRS [4,6,7,28,32].
Our previous study found that CA-125 indicated asymp-
tomatic recurrent cases will benefit from optimal se-
condary CRS [12]. Zang et al. emphasized the number of
recurrent tumors. They stated those patients with solitary
lesions, no ascites at recurrence, achieved initial optimal
surgical outcomes and survival benefit more easily for se-
condary CRS and further confirmed it in a large population
more than one thousand cases [20,21,33]. Berek et al.
reported that recurrent tumor size had an impact on sur-
vival while Park et al. denied the relationship between the
size of the recurrent tumor and survival outcomes [5,29].
In our series, three major prognostic factors affected sur-
vival after secondary CRS: optimal resection after initial
CRS, asymptomatic recurrent status and longer PFS du-
ration after primary treatment.
Morbidity and mortality rates during perioperative
period are also important issues when secondary CRS is
considered in the management of recurrent ovarian cancer.
Postoperative morbidity rates reported to be ranged from
5% to 35% in different trials [5,23,26,34]. In general, sec-
ondary CRS was considered to be a safe procedure in the
management of recurrent EOC [5,35,36]. There was no
operation related deaths in our series.
There are limitations to the present study. Firstly, un-
avoidable selection biases inherent to its retrospective
design. CRS status, chemotherapy regimens and some
additional salvage therapy may have reflected certain se-
lected factors that may influence prognosis, though we
eliminate the influence of consolidation or maintenance
treatment by inclusion criteria. Secondly, given the long
time follow up and the heterogeneity of therapy stra-
tegies used throughout the 23 years study period, includ-
ing the emergence of new regimens such as paclitaxel
based chemotherapy and targeted therapy and so on, it
was impossible to unify the therapy strategy. Thirdly, the
absence of unified recruited standard for secondary CRS
and limited sample size were factors may also cause se-
lection bias. Last but not nest, populations underwent
secondary CRS was relatively young and healthy with agood performance status, and a high likelihood of endure
postoperative chemotherapy. It cannot be translated to all
recurrent EOCs until further studies with broader inclu-
sion criteria are available. Evaluating patients from China
with validation set from America may help to lessen this
unfavorable effect.
In summary, in this study including patients from two
centers with same recruited standard, we found that sec-
ondary CRS has survival benefit to selected patients. The
recruited criterion included asymptomatic recurrent, opti-
mal initial CRS and platinum recurrent with comparatively
longer tumor free interval.
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